Single Escalating-dose, Open-label Study to Assess the Safety and Effect of SANGUINATE Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) After Acute Aneurysmal Subarachnoid Hemorrhage (SAH)

Trial Profile

Single Escalating-dose, Open-label Study to Assess the Safety and Effect of SANGUINATE Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) After Acute Aneurysmal Subarachnoid Hemorrhage (SAH)

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Feb 2017

At a glance

  • Drugs PEG-haemoglobin carbon monoxide (Primary)
  • Indications Cerebral ischaemia; Subarachnoid haemorrhage
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Prolong Pharmaceuticals
  • Most Recent Events

    • 24 Feb 2017 Results presented at the 42nd International Stroke Conference.
    • 26 Oct 2016 Status changed from recruiting to completed.
    • 14 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Jul 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top